Comprehensive treatment of dactylitis in psoriatic arthritis

Journal of Rheumatology

Volumn 41, Issue 11, 2014, Pages 2295-2300

  Rose, Shawn ^a   Toloza, Sergio ^b   Bautista Molano, Wilson ^c   Helliwell, Philip S ^d,e  

^a NATIONAL INSTITUTES OF HEALTH   (United States)

^b Ministry of Health   (Argentina)

^c HOSPITAL MILITAR CENTRAL   (Colombia)

^d UNIVERSITY OF LEEDS   (United Kingdom)

^e BRADFORD TEACHING HOSPITALS NHS FOUNDATION TRUST   (United Kingdom)

Author keywords

Dactylitis; Psoriatic arthritis; Systematic review; Treatment

Indexed keywords

ADALIMUMAB; APREMILAST; BIOLOGICAL PRODUCT; CERTOLIZUMAB PEGOL; CYCLOSPORIN A; DISEASE MODIFYING ANTIRHEUMATIC DRUG; ETANERCEPT; GOLIMUMAB; HYDROXYCHLOROQUINE; INFLIXIMAB; LEFLUNOMIDE; METHOTREXATE; PLACEBO; RECOMBINANT INTERLEUKIN 1 RECEPTOR BLOCKING AGENT; SALAZOSULFAPYRIDINE; USTEKINUMAB; ANTIRHEUMATIC AGENT; BIOLOGICAL FACTOR; NONSTEROID ANTIINFLAMMATORY AGENT;

ARTICLE; DACTYLITIS; DOSAGE SCHEDULE COMPARISON; DRUG DOSE COMPARISON; DRUG EFFICACY; EFFECT SIZE; HUMAN; MULTICENTER STUDY (TOPIC); OUTCOME ASSESSMENT; PRIORITY JOURNAL; PSORIATIC ARTHRITIS; RANDOMIZED CONTROLLED TRIAL (TOPIC); SYSTEMATIC REVIEW; ARTHRITIS, PSORIATIC; COMPLICATION; DRUG COMBINATION; DRUG EFFECTS; EVIDENCE BASED MEDICINE; FEMALE; FINGER JOINT; MALE; PATHOPHYSIOLOGY; PRACTICE GUIDELINE; PROGNOSIS; RISK ASSESSMENT; SEVERITY OF ILLNESS INDEX; TREATMENT OUTCOME;

ANTI-INFLAMMATORY AGENTS, NON-STEROIDAL; ANTIRHEUMATIC AGENTS; ARTHRITIS, PSORIATIC; BIOLOGICAL FACTORS; DRUG THERAPY, COMBINATION; EVIDENCE-BASED MEDICINE; FEMALE; FINGER JOINT; HUMANS; MALE; PRACTICE GUIDELINES AS TOPIC; PROGNOSIS; RISK ASSESSMENT; SEVERITY OF ILLNESS INDEX; TREATMENT OUTCOME;

EID: 84923228720     PISSN: 0315162X     EISSN: 14992752     Source Type: Journal    
DOI: 10.3899/jrheum.140879     Document Type: Article

References (32)

1. Moll JM, Wright V. Psoriatic arthritis. Semin Arthritis Rheum 1973; 3:55-78.
2. Bakewell CJ, Olivieri I, Aydin S.Z., Dejaco C., Ikeda K, Gutierrez M, et al. Ultrasound and magnetic resonance imaging in the evaluation of psoriatic dactylitis: Status and perspectives. J Rheumatol 2013; 40:1951-7.
3. Kavanaugh A, Mease PJ, Gomez-Reino JJ, Adebajo A.O., Wollenhaupt J., Gladman DD, et al. Treatment of psoriatic arthritis in a phase 3 randomised, placebo-controlled trial with apremilast, an oral phosphodiesterase 4 inhibitor. Ann Rheum Dis 2014; 73:1020-6.
4. Mease PJ, Fleischmann R, Deodhar A.A., Wollenhaupt J., Khraishi M, Kielar D, et al. Effect of certolizumab pegol on signs and symptoms in patients with psoriatic arthritis: 24-week results of a Phase 3 double-blind randomised placebo-controlled study (RAPID-PsA). Ann Rheum Dis 2014; 73:48-55.
5. Ritchlin C, Rahman P, Kavanaugh A., Mclnnes IB, Puig L, Li S, et al. Efficacy and safety of the anti-IL-12/23 p40 monoclonal antibody, ustekinumab, in patients with active psoriatic arthritis despite conventional non-biological and biological anti-tumour necrosis factor therapy: 6-month and 1-year results of the phase 3, multicentre, double-blind, placebo-controlled, randomised PSUMMIT 2 trial. Ann Rheum Dis 2014; 73:990-9.
6. Mclnnes IB, Kavanaugh A, Gottlieb A.B., Puig L., Rahman P, Ritchlin C, et al. Efficacy and safety of ustekinumab in patients with active psoriatic arthritis: 1 year results of the phase 3, multicentre, double-blind, placebo-controlled PSUMMIT 1 trial. Lancet 2013; 382:780-9.
7. Gladman DD, Ziouzina O, Thavaneswaran A., Chandran V. Dactylitis in psoriatic arthritis: Prevalence and response to therapy in the biologic era. J Rheumatol 2013; 40:1357-9.
8. Kavanaugh A, van der Heijde D, Mclnnes IB, Mease P, Krueger GG, Gladman DD, et al. Golimumab in psoriatic arthritis: One-year clinical efficacy, radiographic, and safety results from a phase III, randomized, placebo-controlled trial. Arthritis Rheum 2012; 64:2504-17.
9. Kavanaugh A, Mease P. Treatment of psoriatic arthritis with tumor necrosis factor inhibitors: Longer-term outcomes including enthesitis and dactylitis with golimumab treatment in the longterm extension of a randomized, placebo-controlled study (GO-REVEAL). J Rheumatol Suppl 2012; 89:90-3.
10. Cantini F, Niccoli L, Cassara E., Kaloudi O, Nannini C. Sustained maintenance of clinical remission after adalimumab dose reduction in patients with early psoriatic arthritis: A long-term follow-up study. Biologies 2012; 6:201-6.
11. Baranauskaite A, Raffayova H, Kungurov N.V., Kubanova A., Venalis A, Heimle L, et al. Infliximab plus methotrexate is superior to methotrexate alone in the treatment of psoriatic arthritis in methotrexate-naive patients: The RESPOND study. Ann Rheum Dis 2012; 71:541-8.
12. Saougou I, Markatseli TE, Papagoras C, Voulgari P.V., Alamanos Y., Drosos AA. Sustained clinical response in psoriatic arthritis patients treated with anti-TNF agents: A 5-year open-label observational cohort study. Semin Arthritis Rheum 2011; 40:398-406.
13. Karanikolas GN, Koukli EM, Katsalira A, Arida A., Petrou D, Komninou E, et al. Adalimumab or cyclosporine as monotherapy and in combination in severe psoriatic arthritis: Results from a prospective 12-month nonrandomized unblinded clinical trial. J Rheumatol 2011; 38:2466-74.
14. Jung N, Hellmann M, Hoheisel R., Lehmann C, Haase I, Perniok A., et al. An open-label pilot study of the efficacy and safety of anakinra in patients with psoriatic arthritis refractory to or intolerant of methotrexate (MTX). Clin Rheumatol 2010; 29:1169-73.
15. Gladman DD, Sampalis JS, Illouz O, Guerette B. Responses to adalimumab in patients with active psoriatic arthritis who have not adequately responded to prior therapy: Effectiveness and safety results from an open-label study. J Rheumatol 2010; 37:1898-906.
16. Sterry W, Ortonne JP, Kirkham B, Brocq O., Robertson D, Pedersen RD, et al. Comparison of two etanercept regimens for treatment of psoriasis and psoriatic arthritis: PRESTA randomised double blind multicentre trial. BMJ 2010; 340:c147.
17. Kavanaugh A, Mclnnes I, Mease P., Krueger GG, Gladman D, Gomez-Reino J, et al. Golimumab, a new human tumor necrosis factor alpha antibody, administered every four weeks as a subcutaneous injection in psoriatic arthritis: Twenty-four-week efficacy and safety results of a randomized, placebo-controlled study. Arthritis Rheum 2009; 60:976-86.
18. Gottlieb A, Menter A, Mendelsohn A., Shen YK, Li S, Guzzo C, et al. Ustekinumab, a human interleukin 12/23 monoclonal antibody, for psoriatic arthritis: Randomised, double-blind, placebo-controlled, crossover trial. Lancet 2009; 373:633-40.
19. Mease PJ, Ory P, Sharp J.T., Ritchlin CT, Van den Bosch F, Wellborne F, et al. Adalimumab for long-term treatment of psoriatic arthritis: 2-year data from the Adalimumab Effectiveness in Psoriatic Arthritis Trial (ADEPT). Ann Rheum Dis 2009; 68:702-9.
20. Healy PJ, Groves C, Chandramohan M., Helliwell PS. MRI changes in psoriatic dactylitis - extent of pathology, relationship to tenderness and correlation with clinical indices. Rheumatology 2008; 47:92-5.
21. Antoni CE, Kavanaugh A, van der Heijde D, Beutler A, Keenan G, Zhou B, et al. Two-year efficacy and safety of infliximab treatment in patients with active psoriatic arthritis: Findings of the Infliximab Multinational Psoriatic Arthritis Controlled Trial (IMPACT). J Rheumatol 2008; 35:869-76.
22. Kavanaugh A, Krueger GG, Beutler A, Guzzo C., Zhou B, Dooley LT, et al. Infliximab maintains a high degree of clinical response in patients with active psoriatic arthritis through 1 year of treatment: Results from the IMPACT 2 trial. Ann Rheum Dis 2007; 66:498-505.
23. Genovese MC, Mease PJ, Thomson G.T., Kivitz AJ, Perdok RJ, Weinberg MA, et al. Safety and efficacy of adalimumab in treatment of patients with psoriatic arthritis who had failed disease modifying antirheumatic drug therapy. J Rheumatol 2007; 34:1040-50.
24. Healy PJ, Helliwell PS. Measuring dactylitis in clinical trials: Which is the best instrument to use? J Rheumatol 2007; 34:1302-6.
25. Antoni CE, Kavanaugh A, Kirkham B., Tutuncu Z, Burmester GR, Schneider U, et al. Sustained benefits of infliximab therapy for dermatologie and articular manifestations of psoriatic arthritis: Results from the infliximab multinational psoriatic arthritis controlled trial (IMPACT). Arthritis Rheum 2005; 52:1227-36.
26. Antoni C, Krueger GG, de Vlam K, Birbara C, Beutler A., Guzzo C, et al. Infliximab improves signs and symptoms of psoriatic arthritis: Results of the IMPACT 2 trial. Ann Rheum Dis 2005; 64:1150-7.
27. Mease PJ, Gladman DD, Ritchlin C.T., Ruderman EM, Steinfeld SD, Choy EH, et al. Adalimumab for the treatment of patients with moderately to severely active psoriatic arthritis: Results of a double-blind, randomized, placebo-controlled trial. Arthritis Rheum 2005; 52:3279-89.
28. Kaltwasser JP, Nash P, Gladman D., Rosen CF, Behrens F, Jones P, et al. Efficacy and safety of leflunomide in the treatment of psoriatic arthritis and psoriasis: A multinational, double-blind, randomized, placebo-controlled clinical trial. Arthritis Rheum 2004; 50:1939-50.
29. Salvarani C, Cantini F, Olivieri I., Macchioni P, Padula A, Niccoli L., et al. Efficacy of infliximab in resistant psoriatic arthritis. Arthritis Rheum 2003; 49:541-5.
30. Salvarani C, Macchioni P, Olivieri I., Marchesoni A, Cutolo M, Ferraccioli G., et al. A comparison of cyclosporine, sulfasalazine, and symptomatic therapy in the treatment of psoriatic arthritis. J Rheumatol 2001; 28:2274-82.
31. Clegg DO, Reda DJ, Mejias E, Cannon G.W., Weisman MH, Taylor T, et al. Comparison of sulfasalazine and placebo in the treatment of psoriatic arthritis. A Department of Veterans Affairs Cooperative Study. Arthritis Rheum 1996; 39:2013-20.
32. Kaeley GS. Ultrasound imaging module: Report from the GRAPPA 2012 annual meeting. J Rheumatol 2013; 40:1450-2.